Abstract: A method performed by a vehicle feature evaluation system for enabling evaluation of a simulated vehicle-related feature. The vehicle feature evaluation system determines in relation to a road-driven vehicle, with support from a tracking system, an orientation of a head-mounted display, HMD, adapted to be worn by an occupant on-board the road-driven vehicle or position and gaze direction of the occupant. The vehicle feature evaluation system further determines a simulated vehicle design feature to be evaluated in the road-driven vehicle.

Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.

Abstract: Systems and methods are described for providing neutral data access across multiple data structures. One example computer-implemented method includes accessing, by a computing device, a first data element in a data structure and assigning a first unique identifier to the first data element. The method also includes replacing, by the computing device, the first data element in the data structure with the first unique identifier, whereby the first data element is removed from the data structure, and encrypting the first unique identifier of the data structure. The method then also includes storing, by the computing device, the data structure, with the encrypted first unique identifier, in a multi-tenant data structure, for access by a data host.

Abstract: Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

Abstract: Example solutions for using natural language (NL) for complex optimization problems in operations research (OR) include: receiving a user input for an OR problem; generating an NL prompt based on at least the user input, the NL prompt comprising an objective, a variable, input data, and a constraint; using a large language model (LLM), generating a domain-specific language (DSL) passage based on at least the NL prompt, the DSL passage representing the OR problem; transpiling the DSL passage into a programming language passage; solving the OR problem, wherein solving the OR problem comprises executing the programming language passage to generate a problem solution; and generating a report of the problem solution.

Abstract: Systems and methods are described for providing neutral data access across multiple data structures. One example computer-implemented method includes accessing, by a computing device, a first data element in a data structure and assigning a first unique identifier to the first data element. The method also includes replacing, by the computing device, the first data element in the data structure with the first unique identifier, whereby the first data element is removed from the data structure, and encrypting the first unique identifier of the data structure. The method then also includes storing, by the computing device, the data structure, with the encrypted first unique identifier, in a multi-tenant data structure, for access by a data host.

Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.